(Bloomberg) -- Takeda Pharmaceutical Co.'s Actos
diabetes pill may not have the heart-attack risk linked to
GlaxoSmithKline Plc's similar drug, Avandia.
An analysis of Takeda studies, scheduled for completion
this month, may show Actos is free of the cardiac side effect
and could catapult the Takeda drug past Avandia as the world's
best-selling oral diabetes medicine, analysts say. A report by
the Cleveland Clinic in May said Avandia may increase the
chances of heart attacks by 43 percent.
Read more at Bloomberg Exclusive News
diabetes pill may not have the heart-attack risk linked to
GlaxoSmithKline Plc's similar drug, Avandia.
An analysis of Takeda studies, scheduled for completion
this month, may show Actos is free of the cardiac side effect
and could catapult the Takeda drug past Avandia as the world's
best-selling oral diabetes medicine, analysts say. A report by
the Cleveland Clinic in May said Avandia may increase the
chances of heart attacks by 43 percent.
Read more at Bloomberg Exclusive News
No comments:
Post a Comment